Abstract
Objective: The study evaluated the autoimmune profile of COVID-19 positive hospitalised patients. Methods: 40 hospitalised patients with a confirmed diagnosis of COVID-19 were given clinical chemistry and autoimmunity tests. Results: The 40 patients enrolled in our hospital had elevated levels of common inflammatory markers such as C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH) and ferritin. Interleukin-6 (IL-6) concentration was also increased, confirming the key role of this interleukin during severe acute respiratory syndrome (SARS-CoV-2) infection. The most common autoimmunity tests were performed. A significant prevalence of anti-nuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccaromyces cerevisiae (ASCA IgA and IgG) was found. Patients showing a de novo autoantibody response were those with a worse disease prognosis. Conclusion: Our study shows that COVID-19 infection can trigger an autoimmune response and could induce the onset of autoimmune diseases. These data explain why drugs used to treat autoimmune diseases could also be useful in combating SARS-CoV-2 infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
